Pfizer brags of pipeline, refocuses R&D
Pfizer announced that the number of compounds it has in Phase 3 development has grown from 16 to 25 over the past six months, including eight cancer treatments.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.